Oncologie Médicale, Hôpitaux Universitaires Paris Seine-Saint-Denis, Hôpital Avicenne, Bobigny Laboratoire d'Oncoim, Oncology, Bobigny, France.
Oncologie Médicale, Hôpitaux Universitaires Paris Seine-Saint-Denis, Hôpital Avicenne, Bobigny Laboratoire d'Oncoim, Oncology, Bobigny, France.
Clin Lung Cancer. 2019 May;20(3):e393-e401. doi: 10.1016/j.cllc.2018.12.008. Epub 2018 Dec 21.
Lymphoepithelioma-like carcinoma of the lung (LELC) is a rare, Epstein-Barr virus-associated tumor. LELC occurs mostly in young, Asian nonsmokers. A few hundred cases have been reported, mostly from retrospective Asian studies. Optimal treatment has not been clearly established. Treatment options are based on surgery for early stage and on cisplatin-based chemotherapy as first-line therapy for metastatic disease. Prognosis may seem better than for other types of non-small-cell lung cancer, but it remains poor in advanced disease, with a median survival of 24 months, and new treatments options are still warranted. Immunotherapies are now key players in the treatment of non-small-cell lung cancer. However, few data are available for this rare histologic subgroup. We have reviewed the available data on LELC with a focus on the first few cases reported with a response to a programmed cell death 1 inhibitor.
肺淋巴上皮瘤样癌（LELC）是一种罕见的、与 Epstein-Barr 病毒相关的肿瘤。LELC 主要发生在年轻的、不吸烟的亚洲人群中。目前已经报道了几百例病例，主要来自回顾性的亚洲研究。最佳治疗方法尚未明确。治疗选择基于早期手术和以顺铂为基础的化疗作为转移性疾病的一线治疗。预后似乎优于其他类型的非小细胞肺癌，但在晚期疾病中仍然较差，中位生存期为 24 个月，仍然需要新的治疗选择。免疫疗法现在是治疗非小细胞肺癌的关键手段。然而，对于这种罕见的组织学亚组，可用的数据很少。我们回顾了 LELC 的现有数据，重点关注了最初报道的几例对程序性细胞死亡 1 抑制剂有反应的病例。
